You are here

mRNA-1030

Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates

Yahoo Finance

Mon, 04/11/22 - 10:29 am

Moderna Therapeutics

clinical trials